CTX-M-14 and CTX-M-15 enzymes are the dominant type of extended-spectrum beta-lactamase in clinical isolates of Escherichia coli from Korea by 諛곗씪沅� et al.
CTX-M-14 and CTX-M-15 enzymes are the
dominant type of extended-spectrum b-lactamase
in clinical isolates of Escherichia coli from Korea
Wonkeun Song,1 Hyukmin Lee,2 Kyungwon Lee,3 Seok Hoon Jeong,3
Il Kwon Bae,4 Jae-Seok Kim5 and Hyo-Sun Kwak6
Correspondence
Seok Hoon Jeong
kscpjsh@yuhs.ac
1Department of Laboratory Medicine, Hallym University College of Medicine, 150-950, 948-1
Daerim 1-Dong, Youngdeungpo-Gu, Seoul, Republic of Korea
2Department of Laboratory Medicine, Kwandong University College of Medicine, 697-24 Whajung-
Dong, Dukyang-Gu, Goyang, Republic of Korea
3Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei
University College of Medicine, 120-752, 134 Shinchon-Dong, Seodaemu-Gu, Seoul, Republic of
Korea
4Research Institute for Antimicrobial Resistance, Kosin University College of Medicine, 602-030,
34 Amnam-Dong, Suh-Gu, Busan, Republic of Korea
5Department of Laboratory Medicine, Hallym University College of Medicine, 134-701, 150
Sungnae-Gil, Kangdong-Gu, Seoul, Republic of Korea
6Center for Food Safety Evaluation, Korea Food and Drug Administration, 122-704, 231 Jinheung-
Ro, Eunpyung-Gu, Seoul, Republic of Korea
Received 30 June 2008
Accepted 27 October 2008
This study was performed to assess the prevalence and genotypes of plasmid-borne extended-
spectrum b-lactamases (ESBLs) and AmpC b-lactamases in Escherichia coli in Korea. A total of
576 isolates of E. coli was collected from 12 Korean hospitals during May and July 2007. A
phenotypic confirmatory test detected ESBLs in 82 (14.2%) of the 576 E. coli isolates. The most
common types of ESBLs identified were CTX-M-14 (n532) and CTX-M-15 (n527). The
prevalence and diversity of the CTX-M mutants, including CTX-M-15, CTX-M-27 and CTX-M-57,
with significant hydrolytic activity against ceftazidime were increased. PCR experiments detected
genes encoding plasmid-borne AmpC b-lactamases in 15/56 cefoxitin-intermediate or cefoxitin-
resistant isolates, and the most common type of AmpC b-lactamase identified was DHA-1
(n510). These data suggest that the incidence of ESBLs in E. coli has increased as a result of the
dissemination of CTX-M enzymes in Korea. In addition, CTX-M-22, CTX-M-27 and CTX-M-57
have appeared in Korea.
INTRODUCTION
The predominant mechanism for acquired resistance to b-
lactams in Escherichia coli is the synthesis of plasmid-borne
extended-spectrum b-lactamases (ESBLs) and AmpC b-
lactamases. The clavulanic acid (CA)-inhibitory ESBLs are
within molecular class A of the Ambler classification
scheme and confer resistance to oxyimino-cephalosporins
on their bacterial hosts (Paterson & Bonomo, 2005). CTX-
M enzymes are spreading rapidly and are now the
dominant type of ESBL in E. coli in many parts of the
world (Rossolini et al., 2008), although classical TEM and
SHV ESBLs are still dominant in the USA (Bush, 2008). In
Korea, members of the CTX-M-1 and CTX-M-9 clusters
have repeatedly been reported in Enterobacteriaceae since the
first finding of CTX-M-14 in clinical isolates of Shigella
sonnei, E. coli and Klebsiella pneumoniae in 2001 (Pai et al.,
2001). A nationwide survey in 2003 reported 23/246 clinical
isolates (9.3%) of E. coli with an ESBL phenotype, and only
8 of these had CTX-M enzymes (Ryoo et al., 2005).
E. coli is intrinsically susceptible to 7-a-methoxy-cephalo-
sporins [e.g. cefoxitin (FOX) and cefotetan] because of the
low-level expression of the non-inducible species-specific
ampC gene (Philippon et al., 2002). In 1989, Bauernfeind
et al. (1989) described a FOX-resistant K. pneumoniae
isolate, which produced a plasmid-borne AmpC b-
lactamase, named CMY-1, from Korea. Subsequently,
various types of plasmid-borne AmpC enzymes have been
Abbreviations: BA, boronic acid; CA, clavulanic acid; CAZ, ceftazidime;
CTX, cefotaxime; ESBL, extended-spectrum b-lactamase; FOX, cefox-
itin.
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found worldwide (Philippon et al., 2002). In Korea, FOX-
resistant E. coli have increasingly been noted, and a study
performed in 2003 showed that a high portion (53.4%, 62/
116) of FOX resistance in E. coli was due to plasmid-borne
AmpC b-lactamase production (Lee et al., 2006). The aim of
the present study was to determine the prevalence and shift
of plasmid-borne AmpC b-lactamases and ESBLs, with a
special focus on the CTX-M enzymes, in E. coli in Korea.
METHODS
Bacterial strains. Consecutive non-duplicate isolates of E. coli were
collected during May and July 2007 from 12 hospitals in nine cities in
Korea. The isolates were identified using the API-20 E system
(bioMe´rieux). The azide-resistant E. coli J53 was used as a recipient
strain for conjugative transfer. E. coli ATCC 25922 and K. pneumoniae
ATCC 700603 were used as MIC reference strains.
Antimicrobial susceptibility testing. Antibiotic-containing discs
(BBL) were used for routine antibiograms by disc diffusion assay (CLSI,
2006a). The phenotypic confirmatory test for ESBL and/or AmpC b-
lactamase production using boronic acid (BA) as an AmpC b-lactamase
inhibitor was performed as described previously (Song et al., 2007).
MICs were determined by the agar dilution method using Mueller–
Hinton agar (MHA; Difco Laboratories) with an inoculum of 104 c.f.u.
(CLSI, 2006b). The MICs of b-lactams were determined alone or in
combination with a fixed concentration (4 mg ml21) of CA.
Mating-out assays. Conjugation experiments were carried out
between donors and the azide-resistant recipient strain E. coli J53 on
MHA plates. Transconjugants were selected on MHA plates
supplemented with 2 mg ceftazidime (CAZ) ml21 or 2 mg cefotaxime
(CTX) ml21 and 100 mg sodium azide ml21.
Characterization of genes encoding b-lactamases. Detection of
genes encoding plasmid-borne ESBLs and AmpC b-lactamases was
performed by PCR amplification with the primers listed in Table 1, as
described previously (Ryoo et al., 2005; Song et al., 2006). Templates
for PCR amplification in the clinical isolates were plasmid preparations
from the clinical isolates. The PCR products were subjected to direct
sequencing. Both strands of all PCR products were sequenced twice
using an automatic sequencer (model 3730xl; Applied Biosystems).
RESULTS
E. coli isolates harbouring ESBLs
In the study period, clinical E. coli isolates (n5576) were
obtained from outpatients (46.2%), inpatients of general
Table 1. Primers used in this study
PCR target Primer name Primer sequence (5§A3§)
blaCTX-M (CTX-M-1 cluster) CTX-M-1F CCGTCACGCTGTTGTTAGG
CTX-M-1R GACGATTTTAGCCGCCGAC
BM-1F ACTATGGCACCACCAACGAT
FM-1R TTCGGTTCGCTTTCACTTTT
blaCTX-M (CTX-M-2 cluster) CTX-M-2F CGGTGCTTAAACAGAGCGAG
CTX-M-2R CCATGAATAAGCAGCTGATTGCCC
blaCTX-M (CTX-M-8 cluster) CTX-M-8F ACGCTCAACACCGCGATC
CTX-M-8R CGTGGGTTCTCGGGGATAA
blaCTX-M (CTX-M-9 cluster) CTX-M-9F GATTGACCGTATTGGGAGTTT
CTX-M-9R CGGCTGGGTAAAATAGGTCA
blaTEM TEM-F ATGAGTATTCAACATTTCCGT
TEM-R TTACCAATGCTTAATCAGTGA
blaSHV SHV-F CCGGGTTATTCTTATTTGTCGCT
SHV-R TAGCGTTGCCAGTGCTCG
blaPER-1 PER-1F GTTAATTTGGGCTTAGGGCAG
PER-1R CAGCGCAATCCCCACTGT
blaVEB VEB-F ACCAGATAGGAGTACAGACATATGA
VEB-R TTCATCACCGCGATAAAGCAC
blaGES/IBC GES/IBC-F GTTAGACGGGCGTACAAAGATAAT
GES/IBC-R TGTCCGTGCTCAGGATGAGT
blaTLA TLA-F CGCGAAAATTCTGAAATGAC
TLA-R AGGAAATTGTACCGAGACCCT
blaDHA-1 DHA-F GGGGAGATAACGTCTGACCA
DHA-R TAGCCAGATCCAGCAATGTG
blaCMY-1 CMY-1F TCACATCGGCTTCACAGAGC
CMY-1R CCATGGTGATGCTGTCAAAGA
blaCMY-2 CMY-2F CAACACGGTGCAAATCAAAC
CMY-2R CATGGGATTTTCCTTGCTGT
blaACT-1 ACT-1F CGTCATGGTCTCGTCCGTTAG
ACT-1R CCTTGACCTCATCCGGTACCT
W. Song and others
262 Journal of Medical Microbiology 58
wards (46.9%) and inpatients of intensive care units
(6.9%). These isolates were obtained from urine (70.3%),
blood (8.3%), wound (7.4%), sputum (6.2%) and other
samples (7.8%). The phenotypic confirmatory test with BA
detected ESBLs in 82 (14.2%) E. coli isolates. Clinical
isolates with an ESBL phenotype were found in all 12
hospitals (Table 2). Transfer of CAZ or CTX resistance
determinants to the azide-resistant E. coli J53 recipient by
conjugation was successful in 56/82 isolates with an ESBL
phenotype.
PCR experiments detected genes encoding members of the
CTX-M-1 and CTX-M-9 clusters in 42 and 35 isolates,
respectively. The most common types of class A ESBLs
identified were CTX-M-14 (n532) and CTX-M-15
(n527). Genes encoding CTX-M-3 (n510), CTX-M-9
(n52), CTX-M-12 (n51), CTX-M-22 (n52), CTX-M-27
(n51) and CTX-M-57 (n52) were also detected. The bla
gene of SHV-12 was detected in two isolates. Genes
encoding TEM-type b-lactamases were detected in 62/82
isolates, but all were TEM-1. Non-TEM and non-SHV
ESBLs, including PER, VEB, GES and TLA enzymes and
members of the CTX-M-2 and CTX-M-8 clusters, were not
detected in this survey. No ESBL was detected in 4/82
isolates with an ESBL phenotype. These isolates may have
another ESBL-encoding gene not detected with our
primers or may have had false-positive results for ESBL
activity.
E. coli isolates harbouring AmpC b-lactamases
Among 56 FOX-intermediate or FOX-resistant isolates, 26
exhibited positive results in the phenotypic confirmatory
test, i.e. a ¢5 mm increase in the zone diameter of either
the FOX or the cefotetan disc in the presence of BA. PCR
experiments detected genes encoding plasmid-borne
AmpC b-lactamases in 15 isolates. The most common
type of AmpC b-lactamase identified was DHA-1 (n510),
and genes encoding CMY-2 (n53), CMY-10 (n51) and
CMY-11 (n51) were also detected. Nine of the fifteen
isolates simultaneously harboured ESBLs.
Phenotypic characteristics
All of the isolates producing CTX-M-3 (n510), CTX-M-9
(n51), CTX-M-14 (n530) or CTX-M-22 (n51) had more
than eightfold higher MICs for CTX than for CAZ
(Table 3). The isolates producing CTX-M-15, CTX-M-27
or CTX-M-57 exhibited a high level of resistance to CAZ.
Fourteen isolates producing plasmid-borne AmpC b-
lactamases were highly resistant to FOX (MICs ¢128 mg
l21), except for two producing DHA-1. All of the isolates
producing ESBLs exhibited a high level of resistance to
ciprofloxacin (MICs ¢64 mg l21), except for three (data
not shown). A total of 15 out of 82 isolates (18.3%) with
an ESBL phenotype were resistant to amikacin (MICs
¢32 mg l21).
DISCUSSION
Compared with a survey in 1997 (Pai et al., 1999), the
prevalence of ESBL-producing E. coli in Korea has
increased threefold from 4.8 to 14.2%. We have shown
previously that only 3.3% (8/246) of clinical E. coli isolates
produced CTX-M ESBLs in 2003 (Ryoo et al., 2005), but
the prevalence of these enzymes increased to 13.4%
(77/576) in the present study. These results indicate that
the significant increase in ESBL incidence in E. coli may be
due to dissemination of CTX-M enzymes. The incidence of
CTX-M-14 and CTX-M-15 increased from 0.4% (1/246)
and 1.6% (4/246) to 5.6% (32/576) and 4.7% (27/576),
respectively, during this period (Ryoo et al., 2005).
Dissemination of E. coli harbouring members of the CTX-
M-1 and CTX-M-9 clusters has repeatedly been reported in
Asian countries (Hawkey, 2008). CTX-M-14 was the
dominant type of ESBL in E. coli from China (223/325)
and Taiwan (88/128) (Yan et al., 2006; Yu et al., 2007), and
CTX-M-3 was the second most frequent type in these
countries (53/325 and 33/128, respectively). Interestingly,
CTX-M-15 was rarely detected in these countries (2/325
and 2/128, respectively), whilst the enzyme was the second
most dominant type of ESBL in Korea. Three CTX-M
enzymes, including CTX-M-22, CTX-M-27 and CTX-M-
57, were detected for what is believed to be the first time in
Korea in the present study.
It is worth noting that the prevalence and diversity of the
CTX-M mutants, including CTX-M-15, CTX-M-27 and
CTX-M-57, with significant hydrolytic activity against CAZ
have increased (Poirel et al., 2002; Bonnet et al., 2003;
Hopkins et al., 2008). Past reports have shown that the
most common ESBL in E. coli isolates from Korea was
TEM-52 (Pai et al., 1999), but this ESBL was not detected
in our study. Furthermore, SHV-12, which was the most
common ESBL in K. pneumoniae in 2003 (Ryoo et al.,
2005), was detected in only two isolates in this study. Thus,
it appears that CTX-M enzymes with an expanded activity
towards CAZ in E. colimay be replacing TEM-52 and SHV-
12, which confers a high level of resistance against CAZ on
their bacterial hosts.
A survey in 2003 showed that the most common plasmid-
borne AmpC b-lactamase in E. coli isolates from Korea was
CMY-2 (Lee et al., 2006), but it was detected in only three
isolates in this study. The present study showed that the
most common AmpC b-lactamase in E. coli isolates was
DHA-1, an inducible enzyme, and the proportion of AmpC
b-lactamase-producing isolates among the ESBL-pro-
ducing and -non-producing isolates was significantly
different: 11.0% (9/82) versus 1.2% (6/494), respectively.
The present data suggest that the incidence of isolation of
ESBLs in E. coli has increased as a result of the
dissemination of CTX-M enzymes in Korea. The most
common ESBL and AmpC b-lactamase in E. coli were
CTX-M-14 and DHA-1, respectively. In addition, CTX-M-
22, CTX-M-27 and CTX-M-57 have appeared in Korea.
Dissemination of CTX-M enzymes in E. coli
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Table 2. Distribution of ESBL and AmpC b-lactamases in E. coli isolates from Korea
Type of b-lactamase No. of isolates collected from each hospital* Total no. of
isolates
(n5576)
SL1
(n540)
SL2
(n549)
SL3
(n550)
SL4
(n550)
GY
(n550)
SN
(n550)
SW
(n550)
WJ
(n550)
GM
(n549)
BS
(n550)
GJ
(n550)
JJ
(n538)
CTX-M-1 cluster 5 3 2 3 1 3 3 5 4 5 5 3 42
CTX-M-3 1 1 1 3 2 1 1 10
CTX-M-12+DHA-1 1 1
CTX-M-15 5 2 1 1 2 2 2 2 2 2 3 24
CTX-M-15+DHA-1 1 1
CTX-M-15+CMY-2 1 1
CTX-M-15+CMY-10 1 1
CTX-M-22 1 1
CTX-M-22+DHA-1 1 1
CTX-M-57 1 1
CTX-M-57+DHA-1 1 1
CTX-M-9 cluster 2 4 4 2 1 0 6 8 2 3 1 2 35
CTX-M-9 1 1
CTX-M-9+DHA-1 1 1
CTX-M-14 2 2 4 1 1 6 8 2 1 1 2 30
CTX-M-14+SHV-12 1 1
CTX-M-14+CMY-2 1 1
CTX-M-27 1 1
SHV-12+DHA-1 1 1
DHA-1 3 1 4
CMY-2 1 1
CMY-11 1 1
UnidentifiedD 1 1 2 4
Total 7 10 8 6 3 3 10 13 6 10 7 5 88
*The 12 hospitals were in Seoul (SL1–4), Goyang (GY), Sungnam (SN), Suwon (SW), Wonju (WJ), Gumi (GM), Busan (BS), Gwangju (GJ) and Jeju (JJ) in Korea.
DThe BA disc test for ESBLs was positive, but no ESBL or ampC genes were detected.
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Table 3. MICs (mg ml”1) for 82 E. coli isolates with ESBL and/or AmpC enzymes
Type of b-lactamase
(no. of isolates)
FOX CAZ CAZ–CA* CTX CTX–CA*
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
CTX-M-3 (10) 4–32 8 32 2–32 4 32 0.3–1 1 1 16–.256 128 .256 0.1–1 0.3 1
CTX-M-12+DHA-1 (1) 256 256 128 64 32
CTX-M-15 (24) 4–64 16 32 16–.256 64 .256 0.3–4 1 4 128–.256 .256 .256 0.1–1 0.5 1
CTX-M-15+DHA-1 (1) 128 64 2 .256 1
CTX-M-15+CMY-2 (1) 256 64 64 .256 32
CTX-M-15+CMY-10 (1) .256 64 16 256 128
CTX-M-22 (1) 2 1 0.1 32 0.1
CTX-M-22+DHA-1 (1) 256 32 2 32 1
CTX-M-57 (1) 64 32 1 256 0.3
CTX-M-57+DHA-1 (1) 256 64 8 256 2
CTX-M-9 (1) 4 1 0.3 32 0.1
CTX-M-9+DHA-1 (1) 128 2 1 .256 0.5
CTX-M-14 (30) 2–128 16 64 0.3–16 2 8 0.1–2 1 2 16–.256 128 256 0.1–1 0.5 1
CTX-M-14+SHV-12 (1) 16 256 1 64 0.1
CTX-M-14+CMY-2 (1) 256 64 64 128 32
CTX-M-27 (1) 16 256 1 .256 0.3
SHV-12+DHA-1 (1) .256 64 8 16 4
DHA-1 (4) 16–256 0.1–32 0.1–8 0.1–32 0.1–8
CMY-2 (1) 256 16 16 16 32
CMY-11 (1) .256 16 16 128 128
*CA at a fixed concentration of 4 mg ml21.
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